The green light is given to a new drug which is in an experimental stage and slows down the worsening of symptoms.
THE pharmaceutical company Biogen presented "extremely convincing" evidence that the experimental drug of antucanumab (aducanumab) is effective against Alzheimer's disease, as announced by the competent US supervisory authority, the Food and Drug Administration (FDA). This increases the chances that it will be given quickly (until March) marketing authorization for the drug - the first in decades for this neurodegenerative disease- which led to a significant increase against 44% of its shares Biogen on the US stock market.
The drug seems to be able to slow down the deterioration - such as the gradual loss of memory- disease, which affects millions of people around the world. Aducanumab is an antibody specifically designed to remove toxic plaques of the amyloid beta protein., accumulated in patients's brains, destroying their cells.
FDA evaluators judge convincingly and positively the results of the first clinical trial of the drug, although a second test did not work as well, according to Reuters and the Financial Times. The final decision of the FDA does not have to follow the opinion of the special rapporteurs, regarding the marketing authorization for a new medicinal product, but usually this happens.
The support groups of Alzheimer's patients were in favor of the immediate release of the drug, without a third clinical trial, something that some scientists and analysts are asking for, in order not to spend years, until FDA approval. If aducanumab is approved, its annual sales are expected to reach 5,3 billions of dollars by 2025, which explains the early enthusiasm of investors for Biogen, which is based in Massachusetts and its market value has grown by 17 billions of dollars in one day, from 38 in 55 billion. dollars, thanks to the vertical rise of its share.
Source: RES – BPE